
Fennec Pharmaceuticals Investor Relations Material
Latest events

Q2 2025
Fennec Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Fennec Pharmaceuticals Inc
Access all reports
Fennec Pharmaceuticals Inc. is a specialized biopharmaceutical company primarily focused on developing treatments aimed at preventing ototoxicity (hearing loss) caused by platinum-based chemotherapy in pediatric cancer patients. Its flagship product, PEDMARK, represents a formulation of sodium thiosulfate designed to mitigate this side effect, catering to a niche yet critical aspect of pediatric oncology care. The company is headquartered in Research Triangle Park, North Carolina, and its shares are listed on the Nasdaq.
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
FENC
Country
🇺🇸 United States